Detalhe da pesquisa
1.
Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated EGFR Exon 20 insertion-mutated non-small-cell lung cancer.
Future Oncol
; 20(8): 447-458, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37882460
2.
Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations.
Cancers (Basel)
; 15(22)2023 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38001589
3.
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.
Adv Ther
; 40(3): 1187-1203, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36652175